Pharm Exec6h
FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
Adicet Bio reports progress in clinical trial enrollments
Adicet Bio, Inc. (Market cap: $75.8M), a biopharmaceutical company currently rated 'FAIR' by InvestingPro's Financial Health scoring system, has announced updates on the enrollment of its clinical ...
Adicet Bio Gets Fast Track Designation For ADI-001 In Refractory Systemic Lupus Erythematosus
Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...
Māori And Pasifika Health Equity A Focus In Arthritis NZ’s $420K Research Grants
Among the research grants, Taimalieutu Kiwi Tamasese from The Family Centre has been awarded $80,000 in funding to lead a study on gout within Pasifika communities living in the Wellington and ...
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...